In fact some mutations seen in AML including the Fms-like tyrosine kinase 3 (FLT-3) receptor mutations, which occurs in 30-35% of cases (63) and is associated with particularly poor prognosis, are known to enhance ROS production by AML blasts further (64, 65) and high ROS levels are known to drive leukaemogenesis (65, 66). Here, FLT3 is linked to acute myeloid leukemia.